USO 23272

Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Disease Types: Breast Cancer Research

Eligibility Requirements:

• Histologically documented TNBC (ER ≤10% by IHC, PR ≤10% by IHC and HER2 0 or
1+ by IHC or FISH ratio <2 or HER2 gene copy number of <6)
• Early-stage (stage I-III) TNBC scheduled to undergo NAC treatment with curative
intent
• Be willing to provide blood samples before and during treatment
• Have available biopsy tissue
• Pts with current or history of another primary cancer within 5 years of study entry are
excluded
• Pt that started systemic therapy for BC are excluded
• No blood transfusion within two weeks before collection of blood for central ctDNA
testing

For more information on this study CLICK HERE .

Available at:

• Chesapeake
• Hampton (CarePlex)
• Newport News (Port Warwick III)
• Norfolk (Brock Cancer Center)
• Virginia Beach (Princess Anne)
• Williamsburg